Unlock instant, AI-driven research and patent intelligence for your innovation.

Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives

A compound, aryl technology, applied to containing 1, can solve the problems of weak potency of CFTR inhibitors, lack of CFTR specificity, etc.

Inactive Publication Date: 2012-11-28
INST FOR ONEWORLD HEALTH
View PDF34 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] Although CFTR inhibitors have weak potency and lack CFTR specificity, they have been found

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives
  • Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives
  • Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0501] Preparation of 5-(3,5-dichloro-4-hydroxyphenyl)-N-(4-phenoxybenzyl)-1,3,4-oxadiazole-2-carboxamide (Compound 2)

[0502]

[0503] Step 1: 3,5-Dichloro-4-hydroxybenzohydrazide (compound A)

[0504] To a mixture of ethyl 3,5-dichloro-4-hydroxybenzoate (23.5 g, 100 mmol) in ethanol (250 mL) was added hydrazine monohydrate (6 mL, 130 mmol) and the mixture was heated at reflux for 18 h. More hydrazine monohydrate (18 mL, 389 mmol) was added and the mixture was reheated at reflux 9d. The mixture was cooled to room temperature and the resulting solid was collected by filtration, washed with ethanol and dried to afford 11.02 g (50%) of the title compound as a white solid. 1 H NMRδ(ppm)(DMSO-d 6 ): 7.63 (2H, s), 9.19 (1H, s).

[0505] Step 2: Ethyl 2-(2-(3,5-dichloro-4-hydroxybenzoyl)hydrazino)-2-oxoacetate (compound B)

[0506] Ethyl was added dropwise to a stirred mixture of 3,5-dichloro-4-hydroxybenzohydrazide (2.00 g, 9.05 mmol) in anhydrous dichloromethane (50 mL) un...

Embodiment 2

[0545] Preparation of N-(4-phenoxybenzyl)-5-(3-(trifluoromethylsulfonamido)phenyl)-1,3,4-oxadiazole-2-carboxamide (Compound 7)

[0546]

[0547] Step 1: Ethyl 3-(trifluoromethylsulfonamido)benzoate (compound D)

[0548] Trifluoromethanesulfonic anhydride (4.06mL, 24.1mmol) was added dropwise to a stirred solution of ethyl 3-aminobenzoate (3.32g, 20.1mmol) in anhydrous dichloromethane under nitrogen, 3°C ice bath cooling Last for 5min. After 80 min the ice bath was removed and the mixture was stirred for 26 h under nitrogen. The mixture was recooled with an ice bath and more trifluoromethanesulfonic anhydride (4.06 mL, 24.1 mmol) was added, and the mixture was stirred at room temperature for another 16 h. Then, the mixture was cooled to -70°C and triethylamine (6.72 mL, 48.2 mmol) was added dropwise for 20 min, keeping the temperature 4) and evaporate the remaining organic layer. The residue was purified by flash chromatography (silica gel, 15% EtOAc / petroleum ether) to a...

Embodiment 3

[0567] Preparation of N-(3,4-dichlorobenzyl)-N-methyl-5-(4-(trifluoromethylsulfonamido)phenyl)-1,3,4-oxadiazole-2-carboxy Amide (Compound 17)

[0568]

[0569] Step 1: Ethyl 4-(trifluoromethylsulfonamido)benzoate (Compound H)

[0570] Trifluoromethanesulfonic anhydride (4.1 mL, 24.1 mmol) was added dropwise to a stirred solution of ethyl 4-aminobenzoate (3.30 g, 20 mmol) in anhydrous dichloromethane under nitrogen, 3 °C ice bath cooling, and 5min. After 80 min the ice bath was removed and the mixture was stirred under nitrogen for 26 h. The mixture was recooled with an ice bath and more trifluoromethanesulfonic anhydride (4.06 mL, 24.1 mmol) was added and stirred at room temperature for another 16 h. The mixture was then cooled to -70°C and triethylamine (6.72 mL, 48.2 mmol) was added dropwise for 20 min, keeping the temperature 4 ) the remaining organic layer and evaporated. The residue was purified by flash chromatography (silica gel, 15% EtO Ac / petroleum ether) to af...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
electrical resistanceaaaaaaaaaa
Login to View More

Abstract

The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-2 or encompassed by formulas I-IV) or compositions comprising these compounds, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit under 35 U.S.C. §119(e) of US Provisional Application No. 61 / 171,056, filed April 20, 2009, the entire contents of which are incorporated herein by reference. technical field [0003] The present application and invention disclose 1,3,4-oxadiazole-containing compounds that inhibit the transport of ions (eg, chloride ions) across cell membranes expressing the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Compounds that inhibit CFTR and derivatives and compositions thereof, pharmaceutical dosage forms and methods of use are described in more detail below. Background technique [0004] Diarrhea is often caused by a variety of bacterial, parasitic and viral infections and is a major threat in areas where drinking water is scarce. Preventing exposure to pathogens that cause diarrhea is the only way to avoid infection. Unfortunately, this will require substantial i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/41
CPCC07D271/10C07D413/06A61P1/00A61P1/12A61P3/02A61P9/06A61P13/12A61P15/08
Inventor 迈克尔·杰弗里·尼尔·罗素凯文·詹姆斯·多伊尔
Owner INST FOR ONEWORLD HEALTH